BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 21159634)

  • 1. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response.
    Cho HM; Rosenblatt JD; Tolba K; Shin SJ; Shin DS; Calfa C; Zhang Y; Shin SU
    Cancer Res; 2010 Dec; 70(24):10121-30. PubMed ID: 21159634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors.
    Triulzi C; Vertuani S; Curcio C; Antognoli A; Seibt J; Akusjärvi G; Wei WZ; Cavallo F; Kiessling R
    Cancer Res; 2010 Oct; 70(19):7431-41. PubMed ID: 20823150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.
    Dela Cruz JS; Morrison SL; Penichet ML
    Vaccine; 2005 Sep; 23(39):4793-803. PubMed ID: 15967544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
    Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
    J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
    Zhang T; Barber A; Sentman CL
    Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity.
    Peng LS; Penichet ML; Morrison SL
    J Immunol; 1999 Jul; 163(1):250-8. PubMed ID: 10384123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
    Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
    Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
    Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
    Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of NKG2D and its ligand in mouse heart allografts may have a role in acute rejection.
    Feng L; Ke N; Ye Z; Guo Y; Li S; Li Q; Li Y
    Transplant Proc; 2009 Dec; 41(10):4332-9. PubMed ID: 20005394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition.
    Mamessier E; Sylvain A; Bertucci F; Castellano R; Finetti P; Houvenaeghel G; Charaffe-Jaufret E; Birnbaum D; Moretta A; Olive D
    Cancer Res; 2011 Nov; 71(21):6621-32. PubMed ID: 21937679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
    Dela Cruz JS; Trinh KR; Chen HW; Ribas A; Morrison SL; Penichet ML
    Mol Immunol; 2006 Feb; 43(6):667-76. PubMed ID: 15908002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
    Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
    Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted delivery of an antibody-mutant human endostatin fusion protein results in enhanced antitumor efficacy.
    Shin SU; Cho HM; Merchan J; Zhang J; Kovacs K; Jing Y; Ramakrishnan S; Rosenblatt JD
    Mol Cancer Ther; 2011 Apr; 10(4):603-14. PubMed ID: 21393427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immuno-gene therapy with adenoviruses expressing fms-like tyrosine kinase 3 ligand and CD40 ligand for mouse hepatoma cells in vivo.
    Yanagi K; Nagayama Y; Nakao K; Saeki A; Matsumoto K; Ichikawa T; Ishikawa H; Hamasaki K; Ishii N; Eguchi K
    Int J Oncol; 2003 Feb; 22(2):345-51. PubMed ID: 12527933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence.
    Wang F; Ren J; Qiu XC; Wang LF; Zhu Q; Zhang YQ; Huan Y; Meng YL; Yao LB; Chen SY; Xu YM; Yang AG
    Clin Cancer Res; 2010 Apr; 16(8):2284-94. PubMed ID: 20371697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
    Liu A; Hu P; Khawli LA; Epstein AL
    Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors.
    Gao Y; Whitaker-Dowling P; Griffin JA; Barmada MA; Bergman I
    Cancer Gene Ther; 2009 Jan; 16(1):44-52. PubMed ID: 18654610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.
    Helguera G; Dela Cruz JS; Lowe C; Ng PP; Trinh R; Morrison SL; Penichet ML
    Vaccine; 2006 Jan; 24(3):304-16. PubMed ID: 16125282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.
    Diefenbach A; Jamieson AM; Liu SD; Shastri N; Raulet DH
    Nat Immunol; 2000 Aug; 1(2):119-26. PubMed ID: 11248803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.